Browse the evidence

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly reduces the 10-year risk of developing type 2 diabetes in adults with overweight or obesity compared to placebo.

If you have obesity or overweight with related health issues, adding once-weekly semaglutide 2.4 mg to your lifestyle changes can significantly lower your 10-year risk of developing type 2 diabetes compared to lifestyle changes alone. This benefit is most pronounced in those with higher baseline risk or prediabetes, and maintaining the treatment appears necessary to sustain these lower risk scores.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) and multi-agonists (e.g., retatrutide) produce superior weight loss compared to single GLP-1 receptor agonists by synergistically enhancing anorectic effects in the CNS and reducing emetogenic side effects.

If current GLP-1 therapy is ineffective or causes intolerable nausea, discuss dual (GLP-1/GIP) or multi-agonists (GLP-1/GIP/Glucagon) with your provider. These newer agents target multiple pathways to potentially yield greater weight loss and fewer GI side effects.

Low-carbohydrate diets significantly improve glycemic control (HbA1c and FPG) and lipid profiles (reduced triglycerides, increased HDL) in overweight or obese patients with Type 2 Diabetes Mellitus compared to control diets.

If you have Type 2 Diabetes and are overweight, reducing your carbohydrate intake to under 26% of your daily calories can significantly lower your HbA1c and fasting blood sugar. It also improves your blood fat profile by lowering triglycerides and raising good HDL cholesterol, without negatively affecting your LDL. You should work with your doctor to adjust diabetes medications (like insulin) to avoid low blood sugar as you start this diet.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to monotherapy by leveraging synergistic mechanisms of both incretin hormones.

Tirzepatide is a weekly injection that mimics two gut hormones (GIP and GLP-1) to improve blood sugar control and promote significant weight loss. It is a newer option for T2DM and obesity, offering benefits beyond what single-hormone therapies provide.

Resmetirom (80-100 mg daily) is the first FDA-approved pharmacotherapy for MASH with fibrosis, demonstrating significant improvement in liver fibrosis and MASH resolution compared to placebo.

Resmetirom is the first approved drug for MASH with fibrosis. It works by targeting thyroid hormone receptors in the liver to reduce fat and inflammation. Take 80mg or 100mg daily. Expect possible mild stomach issues, but the drug has proven to improve liver scarring in clinical trials.

Tirzepatide (10-15 mg weekly) is more effective than placebo in resolving MASH without worsening fibrosis, showing substantial weight loss and metabolic improvements.

Tirzepatide (10-15mg weekly) is more effective than placebo for resolving MASH without worsening fibrosis. It causes significant weight loss and has an acceptable safety profile.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (17.8% placebo-subtracted) in individuals with obesity without diabetes.

Tirzepatide is a once-weekly injection that significantly reduces body weight in people with obesity, even without diabetes. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and improve metabolism. While effective, it can cause temporary gastrointestinal issues like nausea, which usually subside as your body adjusts.

Semaglutide 2.4 mg weekly produces significant weight loss (14.9% reduction) in individuals with obesity.

Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management. It significantly reduces body weight by mimicking the GLP-1 hormone, which helps control appetite. Common side effects include gastrointestinal issues, which often improve over time.

GLP-1 receptor agonists (e.g., semaglutide) are the most efficacious weight-loss drugs currently available in clinical use.

GLP-1 receptor agonists like semaglutide are currently the most effective pharmaceutical option for weight loss. If you are struggling with obesity, this class of medication offers the highest potential for efficacy, though you must manage potential side effects like nausea. Discuss with your doctor if this injectable treatment is appropriate for you.

GLP-1 agonists (specifically Semaglutide and Liraglutide) induce significant weight loss (≥15%) which improves Obstructive Sleep Apnoea (OSA) severity, measured by Apnoea-Hypopnoea Index (AHI), particularly in patients who cannot tolerate CPAP.

If you have OSA and struggle with CPAP or cannot lose enough weight through diet alone, GLP-1 agonists like Semaglutide (2.4mg weekly) are a clinically proven option to reduce sleep apnea severity. Be prepared for potential gastrointestinal side effects and the likelihood that you may need to stay on the medication long-term to keep the weight off and your airway open.

GLP-1 receptor agonists (liraglutide 3 mg and semaglutide 2.4 mg) produce significantly greater weight loss in patients with obesity compared to orlistat, with average losses of 7 kg more than control groups in meta-analyses.

If you have obesity and a related health condition (like diabetes or high blood pressure), GLP-1 medications (liraglutide or semaglutide) are significantly more effective for weight loss than older drugs like orlistat. You must combine the medication with a healthy diet and exercise. Start with the lowest dose and increase slowly to minimize stomach upset, which usually goes away.

GLP-1 receptor agonists (GLP-1RAS) significantly reduce body weight and improve glucose tolerance in prediabetic patients, offering a potent alternative to metformin, particularly for those with obesity.

GLP-1 receptor agonists (like semaglutide or liraglutide) are injectable medications that significantly reduce weight and improve blood sugar in prediabetes. They are particularly effective for overweight individuals. Side effects like nausea are common initially. They are more potent than metformin for weight loss but require injection.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered as a once-weekly injection, produces significantly greater weight loss and glycemic control in adults with obesity and type 2 diabetes compared to placebo, semaglutide, and long-acting insulin analogs.

If you have obesity and Type 2 Diabetes, standard diet and exercise may not be enough to control your blood sugar or achieve significant weight loss. Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones to improve insulin response, reduce appetite, and slow digestion. Clinical data shows it leads to greater weight loss than placebo, semaglutide, and insulin analogs. However, it carries risks of gastrointestinal side effects (nausea, vomiting) and is contraindicated for those with a history of medullary thyroid cancer. Consult a doctor to see if this high-efficacy intervention is appropriate for your specific health profile.

Subcutaneous tirzepatide is the most cost-effective anti-obesity medication for adults without diabetes over a 68-week period, demonstrating superior incremental cost-effectiveness compared to oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide.

For adults without diabetes seeking weight loss, subcutaneous tirzepatide offers the best value for money among current GLP-1 based therapies over a 68-week period. It is more cost-effective than oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide. While oral semaglutide is a good alternative for those who dislike injections, tirzepatide provides superior cost-effectiveness. Patients should discuss these options with their healthcare provider, considering factors like injection preference, insurance coverage, and potential side effects.

Resistance exercise extends the duration of the muscle protein synthesis response to protein ingestion, thereby allowing for greater cumulative muscle growth compared to protein ingestion alone.

To maximize muscle growth, you must combine resistance exercise with protein intake. Exercise extends the time your muscles are sensitive to protein (up to 24-48 hours). Simply eating protein without exercising will not build muscle; the protein will be used for energy instead.

Optimizing medications by switching from weight-gain-causing drugs (antipsychotics, sulfonylureas, insulin) to weight-neutral or weight-loss agents (aripiprazole, SGLT2i, GLP-1 RA) facilitates weight management.

If you are gaining weight on psychiatric or diabetes medications, ask your doctor about switching. Some drugs cause significant weight gain, while others are weight-neutral or help you lose weight (like SGLT2 inhibitors or GLP-1 agonists). This optimization can support your weight loss efforts without compromising your primary health condition.

Significant weight loss achieved through very low calorie diets (VLCD) or bariatric surgery can preserve and enhance beta-cell function in type 2 diabetes, particularly in patients with short disease duration.

If you have Type 2 Diabetes, especially if diagnosed recently, significant weight loss is the most effective way to restore your pancreas's ability to make insulin. This can be achieved through bariatric surgery or a strict 600-calorie daily diet for a short period (1-8 weeks). This is not just about weight loss; it is about 'resting' the beta-cells to restore their function.

GLP-1 receptor agonists (GLP-1 RAs) are effective for preoperative weight loss in orthopaedic surgery patients with obesity and type-2 diabetes, reducing surgical risk without increasing postoperative complications.

If you are having orthopaedic surgery and take GLP-1s (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. You likely need to stop taking them a week before (for weekly doses) or on the day of (for daily doses) to prevent stomach issues during anesthesia. This helps ensure your surgery goes smoothly and reduces infection risk.

Combined resistance training (upper and lower body) produces significantly greater improvements in muscle-related hormonal markers (follistatin, follistatin/myostatin ratio, adiponectin) and inflammatory reduction (myostatin, CRP) compared to isolated upper or lower body training in overweight and obese men, primarily driven by higher total training volume.

If you are overweight or obese and want to maximize hormonal health and reduce inflammation through resistance training, prioritize a combined upper and lower body routine over isolating specific body parts. Perform this routine 3 times per week, progressively increasing the weight (from 50% to 80% of your one-rep max) over 12 weeks. This approach yields significantly better improvements in muscle-building hormones and inflammation reduction than training only your upper or lower body.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, while offering cardioprotective benefits through lipid lowering and anti-inflammatory mechanisms.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to lower blood sugar, reduce appetite, and protect the heart. It is more effective than older GLP-1 drugs for weight loss and blood sugar control. Start with a low dose to minimize stomach upset, and work with your doctor to find the right dose for you.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) produce clinically significant weight loss (approx. 10-22%) but are associated with high rates of gastrointestinal adverse events.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (10-22%+), but they come with notable gastrointestinal side effects. They are most effective when combined with lifestyle changes and psychological support, rather than used in isolation.

Adjunctive use of GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) in adults with Type 1 Diabetes significantly improves glycemic control, reduces total daily insulin doses, and promotes weight loss compared to placebo, without increasing the risk of severe hypoglycemia.

If you have Type 1 Diabetes and struggle with weight or high insulin doses, ask your doctor about adding a GLP-1 medication like semaglutide or liraglutide. These drugs can help lower your blood sugar, reduce the amount of insulin you need, and help you lose weight. Be aware that you might experience stomach upset, but starting with a low dose and increasing slowly can help manage this. This is an off-label use for T1D, so discuss the risks and benefits with your healthcare provider.

Consuming 20–40g of whey protein immediately after resistance exercise significantly increases myofibrillar fractional synthetic rate (FSR) and activates the AKT/mTOR signaling pathway (AKT, mTOR, 4E-BP1, p70S6K, rpS6) in healthy adults, thereby extending the post-exercise anabolic window.

For healthy adults engaging in resistance training, consuming 20-40g of whey protein around your workout (either immediately after or up to 45 minutes before) significantly boosts muscle protein synthesis compared to placebo. This strategy activates the AKT/mTOR pathway, which drives muscle repair and growth. You do not need to consume excessive amounts (>40g) to see benefits, and pre-workout consumption may even offer a slight edge in FSR magnitude for some protocols.

Omega-3 fatty acid supplementation (≥1 g/day) supports muscle quality, cardiovascular health, and reduces inflammation during GLP-1RA treatment.

Take at least 1 gram of Omega-3 fatty acids daily. This helps protect your heart, reduces inflammation, and may support muscle quality while you lose weight.